官方服务：
资源简介：
NSCLC cells treated with Gefitinib
应用场景：
创建时间：
2011-01-27
相关数据集
Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Taxus chinensis against NSCLC
Network pharmacology analysis data, including analysis process and results.
科学数据银行2022-06-21 更新40
Baseline characteristics.
Background Retrospective evidence indicated potential survival benefit of consolidative stereotactic radiotherapy (SRT) in patients with metastatic driver mutation-negative non-small cell lung cancer
NIAID Data Ecosystem30
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
Median overall survival and progression-free survival hazard ratios (HRs) and 95% Credible Intervals for cabazitaxel, abiraterone and enzalutamide using Bayesian fixed effects modeling.
NIAID Data Ecosystem20
Studies included in the meta-analysis.
Abbreviations: MLND, mediastinal lymph node dissection; MLNS, mediastinal lymph node sampling; NSCLC, non-small cell lung cancer; ND, not derived.Studies included in the meta-analysis.
Figshare2015-12-02 更新40
DataSheet13_Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.zip
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. Howeve
NIAID Data Ecosystem20
